MARKET

XENE

XENE

Xenon Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.95
-0.01
-0.09%
Opening 13:18 03/31 EDT
OPEN
10.96
PREV CLOSE
10.96
HIGH
11.60
LOW
10.69
VOLUME
109.41K
TURNOVER
--
52 WEEK HIGH
18.45
52 WEEK LOW
7.00
MARKET CAP
382.77M
P/E (TTM)
-7.0993
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XENE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XENE stock price target is 22.20 with a high estimate of 25.00 and a low estimate of 15.00.

EPS

XENE News

More
  • Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19
  • GlobeNewswire · 3h ago
  • Xenon Pharmaceuticals Says Cash And Equivalents Were ~$235M At End Of Feb.
  • Benzinga · 4h ago
  • Edited Transcript of XENE earnings conference call or presentation 9-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 4d ago
  • Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • GlobeNewswire · 4d ago

Industry

Biotechnology & Medical Research
-1.79%
Pharmaceuticals & Medical Research
-0.74%

Hot Stocks

Symbol
Price
%Change

About XENE

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
More

Webull offers kinds of Xenon Pharmaceuticals Inc stock information, including NASDAQ:XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions.